

EPA – Icahn School of Medicine at Mount Sinai – MTA #1335-20

AGR-21143

**MATERIALS TRANSFER AGREEMENT**

**Provider: U.S. EPA Center for Computational Toxicology & Exposure (CCTE)**

**Provider Contact (not signator)**

Name: Elin Ulrich

Address: 109 TW Alexander Drive, MD-D205-05, RTP, NC 27711

Phone: 919-541-3717

Email: ulrich.elin@epa.gov

**Recipient: Icahn School of Medicine at Mount Sinai**

**Recipient Contact (not signator)**

Name: Douglas Walker

Address: 1428 Madison Ave, New York, NY 10029

Phone: 212-241-9891

Email: douglas.walker@mssm.edu

1. Provider agrees to transfer to Recipient the following Research Material:

Per- and Polyfluoroalkyl Substances (PFAS) Standard Library. The list of PFAS chemicals is provided in a separate file.

2. This Research Material may not be used in human subjects. The Research Material will be used only for research purposes by Recipient’s investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for screening, production or sale, for which a commercialization license may be required. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material.

**EPA ONLY:** If the data or material that are being transferred constitute human subjects research, please visit the following intranet site to determine if your project needs review and approval by the HSRRO: <http://intranet.ord.epa.gov/p2/hsr/human-subjects-review>

There is no Human Subjects material being used in this research.

Research Plan reviewed and approval by HSRRO:

Name \_\_\_\_\_ Date \_\_/\_\_/\_\_\_\_

3. If the data or material that are being transferred involve life sciences research, or more specifically any of the select agents or toxins listed and/or the definitions provided in EPA Order 1000.19 *Policy and Procedures for Managing Dual Use Research of Concern*, then Principal Investigators should consult EPA’s Institutional Contact for Dual Use Research of Concern

EPA – Icahn School of Medicine at Mount Sinai – MTA #1335-20

AGR-21143

(ICDUR) at [DURC@epa.gov](mailto:DURC@epa.gov) before completing the following section. If not, then check the first box below.

- This research does not meet any of the definitions of Dual Use Research of Concern (DURC) and no additional review or oversight are required. The PI must report to the ICDUR any results or changes in the research that meet any of the definitions of DURC.
- This research meets one or more definitions of DURC and requires additional oversight under the *USG Policy for Institutional Oversight of DURC*. The parties to this Agreement are required to comply with EPA Order 1000.19, *Policy and Procedures for Managing Dual Use Research of Concern*.

For information about DURC and EPA Order 1000.19, please visit:

<http://intranet.ord.epa.gov/homeland-security/dual-use-research-concern-durc-policies>

4. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows:

The per- and polyfluoroalkyl substances (PFAS) library will be analyzed using liquid chromatography with high-resolution mass spectrometry (LC-HRMS) and gas chromatography with high-resolution mass spectrometry (GC-HRMS) systems located at the Frank R. Lautenberg Environmental Health Laboratory at Mount Sinai. Samples will be treated with acetonitrile or ethyl acetate prior to analysis by HRMS. Each standard will be used to generate accurate mass m/z, retention time, isotope distributions and MSMS spectra. The resulting library will be shared with the Provider and used by both parties to assess 1) standard quantity; 2) presence of impurities; 3) optimum conditions for detection; 4) detection sensitivity. Mass spectral results from this library will be uploaded to publicly available databases for use by the research community.

5. Recipient may publish or otherwise publicly disclose the results of the Research Project. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge Provider's contribution of this Research Material unless requested otherwise.

6. This Research Material represents a significant investment on the part of Provider and is considered proprietary to Provider. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under his/her direct supervision without advance written approval of Provider. Provider reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed, the Research Material will be returned to the Provider or disposed, if directed by Provider.

7. This Research Material is provided as a service to the research community. It is being supplied to Recipient with no warranties, express or implied, including any warranty of merchantability or

EPA – Icahn School of Medicine at Mount Sinai – MTA #1335-20

AGR-21143

fitness for a particular purpose. Provider makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.

8. Recipient shall retain rights, title and interest in and to any results, invention or other intellectual property made by its faculty, staff, employees, agents, or students in the course of the Research Project. However, if said invention contains any portion of the Research Material, are derived from the Research Material, or could not have been produced but for the use of the Research Material, Recipient agrees to contact the Provider to determine what ownership interests, if any, the Provider may have, and, where applicable, to negotiate in good faith the terms of a commercial license. Inventorship in said invention shall be determined according to United States patent law.

9. When Provider is the EPA: Recipient agrees not to claim, infer, or imply endorsement by the Government of the United States of America (hereinafter referred to as “Government”) of the Research Project, the institution, or personnel conducting the Research Project or any resulting product(s). Recipient agrees to hold the Government harmless for all liabilities, demands, damages, expenses, and losses arising out of Recipient’s use for any purpose of the Research Material.

10. Either Party shall have the right to terminate this Agreement at any time if a Party breaches any of the terms of this Agreement. Upon termination, Recipient shall return to the Provider all unused portions of the Research Materials.

11. Will EPA develop any products or services from information or materials provided by the Recipient?

Yes – go to item A

No – skip to #12 (next clause)

Item A: The EPA laboratory must coordinate on matters related to Quality Assurance with their QA Specialist.

If necessary, the Laboratory will develop/has developed a Quality Assurance Plan in coordination with the Quality Assurance Specialist.

No QA requirements are needed.

12. All notices pertaining to or required by this Agreement shall be in writing and shall be signed by an authorized representative and shall be delivered by hand (including private courier mail service) or sent by certified mail, return receipt requested, with postage prepaid, addressed as follows:

EPA – Icahn School of Medicine at Mount Sinai – MTA #1335-20

AGR-21143

**Provider’s Contact Information:**

Russell Thomas, Ph.D.  
Director, Center for Computational Toxicology & Exposure  
109 T.W. Alexander (MD-D143-02)  
Research Triangle Park, NC 27711  
919.541.5776  
thomas.russell@epa.gov

**With a copy to:**

Kathleen Graham  
FTTA Program Coordinator  
graham.kathleen@epa.gov  
(303) 312-6137  
FTTA@epa.gov

**Recipient’s Contact Information:**

**If to Mount Sinai:**

Icahn School of Medicine at Mount Sinai  
Mount Sinai Innovation Partners  
One Gustave L. Levy Place, Box 1675  
New York, NY 10029  
Attention: Executive Vice President

**With a copy for legal notices only to:**

Icahn School of Medicine at Mount Sinai  
One Gustave L. Levy Place, Box 1099  
New York, NY 10029  
Attention: Office of General Counsel

13. Paragraphs 2, 5, 7, 8, and 9 shall survive termination.

14. The undersigned Provider and Recipient expressly certify and affirm that the contents of any statements made herein are truthful and accurate.

15. This agreement shall enter into force as of the date of the last signature of the parties and shall remain in effect for two years from said date.

EPA – Icahn School of Medicine at Mount Sinai – MTA #1335-20

AGR-21143

**Authorized Representative of Institution SIGNATURES**

**FOR THE RECIPIENT**

*Principal Investigator:*

DocuSigned by:  
[Redacted Signature]  
By: \_\_\_\_\_  
Douglas Walker  
Recipient Scientist  
douglas.walker@mssm.edu

Date \_\_\_\_\_

*Authorized Representative of Institution:*

DocuSigned by:  
[Redacted Signature]  
By: \_\_\_\_\_  
Sybil Lombillo  
Managing Director, Mount Sinai Innovation Partners  
sybil.lombillo@mssm.edu

Date \_\_\_\_\_

**FOR THE PROVIDER**

[Redacted Signature]  
By: \_\_\_\_\_  
Russell Thomas  
Director, Center for Computational Toxicology & Exposure  
thomas.russell@epa.gov

Date \_\_\_\_\_